CYRX Earnings

CYRX reported its FY2025Q4 earnings on 2026-03-03, showcasing a revenue of against an estimate of 42.81M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.19 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CYRX's FY2025Q4 earnings announcement on 2026-03-03, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CYRX's stock price tends to shift by an average of 10.24% in the 10 days leading up to earnings and 5.43% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CYRX's annual revenue to reach 42.94M, while the EPS is projected at -0.22. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CYRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CYRX's stock price typically moves by 10.24% in the 10 days before its earnings and 5.43% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.22 and revenue of 42.94M.

The earnings call highlights reaffirmed revenue guidance for 2025 and a strong outlook for commercial revenue growth, supported by FDA approvals. The strategic partnership with DHL is expected to enhance capabilities, and there is optimism for regulatory approvals. While there are some uncertainties, such as the gene therapy pause and lack of profitability guidance for 2026, the overall sentiment is positive, particularly with the potential for market expansion and strategic initiatives. The Q&A session further supports this with positive analyst sentiment and no significant concerns about market exits.